We have changed our domainWe have changed servers and operate Career|edu under a different domain. Our services will remain unchanged and we will continue to post the best career openings for the academic world at our new domain.
Go back to the Job List
Modeling and Simulation of Chimeric Antigen Receptor (CAR) T Cell TherapyPosted by: Postdoc positions by NIH
Posted date: 2019-Mar-29
An ORISE research fellowship is available immediately at the Food and Drug Administration (FDA) in Silver Spring, Maryland. The successful candidate will participate in the development of a quantitative key event relationships model to simulate and predict immune responses of Chimeric Antigen Receptor (CAR) T cells. The end goal of this project is the development of a computational tool to enhance efficacy and safety evaluation of current and next-generation of engineered therapeutic products, leading to personalized, optimal treatment regimens for patients undergoing CAR T cell therapy. Under the guidance of a mentor, the participant will help develop and apply novel techniques to model and simulate interactive cellular components of CAR T Cells, as well as perform literature review, data collection/database curation, model development, presentation of research results, and preparation of scientific manuscripts.
This position is a post-doctoral fellowship through the Oak Ridge Institute for Science and Education (ORISE).Qualifications:
The qualified candidate should have received a doctoral degree in one of the relevant fields or be currently pursuing the degree and will reach completion by June 1, 2019. Degree must have been received within five years of the appointment start date. This position is only open for US citizens, permanent residents (Green Card holders) or individuals residing in US for 3 years during the last 5 years on a valid US visa. Preferred skills/experience are
Candidates will be offered competitive salary and health benefits.To Apply:
Highly motivated candidates should apply through Zintellect.com (Reference Code: FDA-CBER-2019-0022)